May 06, 2024 / 08:30PM GMT
Operator
Good afternoon and welcome to Enanta Pharmaceuticals Fiscal Second Quarter Financial Results Conference Call. At this time, all participants are on a listen only mode. There will be a question and answer session. At the end of the prepared remarks, please be advised that this call is being recorded. I would now like to turn the call over to Jennifer Viera, Investor Relations.
Please go ahead.
Jennifer Viera - Enanta Pharmaceuticals, Inc. - IR
Thank you, operator, and thanks to everyone for joining us this afternoon. The news release with our fiscal second quarter financial results. It was issued this afternoon and is available on our website.
Making remarks on today's call are Dr. Jay Luly, President and Chief Executive Officer; and Paul Mellett, our Chief Financial Officer; Dr. Scott Rottinghaus, our Chief Medical Officer; and Dr. Tara Kieffer, our Chief Product Strategy Officer, will be available during the Q&A portion of the call.
Before we begin with our formal remarks, we want to remind you that we will be making forward
Q2 2024 Enanta Pharmaceuticals Inc Earnings Call Transcript
May 07, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers